Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.38 |
| ▸ | SGK1 | O00141 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11918017 | 0.84 | NPSR1 (0.38) | NPSR1RXFP1ADORA2AADORA1SGK1 | |
| SCHEMBL1654710 | 0.81 | RHEB (0.40) | TRPV1CYP1A2ADORA2AADORA1ABL1 | |
| SCHEMBL11913448 | 0.79 | CYP1A2 (0.38) | TRPV1NPSR1RXFP1CYP1A2SGK1 | |
| SCHEMBL13649848 | 0.74 | ADORA1 (0.60) | NPSR1RXFP1ADORA2AADORA1TSHR | |
| SCHEMBL12888472 | 0.74 | CYP1A2 (0.42) | TRPV1CYP1A2ABL1 | |
| SCHEMBL11913443 | 0.73 | ADORA2A (0.31) | ADORA2AADORA1 | |
| SCHEMBL11913445 | 0.73 | ADORA2A (0.31) | ADORA2AADORA1 | |
| SCHEMBL4251648 | 0.72 | ADORA1 (0.46) | ADORA2AADORA1TYMSTRPA1 | |
| SCHEMBL12888333 | 0.71 | ABL1 (0.44) | TRPV1CYP1A2ABL1 | |
| SCHEMBL4251467 | 0.71 | ABL1 (0.43) | ADORA2AADORA1ABL1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202690-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202690-A1 | HERBICIDAL COMPOUNDS | DDT, HAO2, HAAO | TRPV1 2865/4885NPSR1 1646/4885RXFP1 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.